Nuventra Pharma Sciences is now Allucent. Learn more here.

Take a deeper dive

News & Events

Nuventra Ranks on Inc. 5000 List for Eighth Consecutive Year

Nuventra is proud to announce that it has once again been ranked on the Inc. 5000 list for 2021. This marks the eighth year in a row that Nuventra has been recognized by Inc. Magazine as one of the fastest-growing privately held companies in the country.

In May of 2021, Nuventra was acquired by CATO SMS, a global provider of clinical research solutions including consulting and full service clinical trial operations with a focus on small and emerging companies. The acquisition is part of CATO SMS’ strategic expansion to better fulfill the drug development needs of biopharmaceutical companies from strategy to approval.

With the addition of Nuventra, CATO SMS offers customers cutting-edge clinical pharmacology services that include strategic consulting, pharmacokinetics/pharmacodynamics (PK/PD), pharmacometrics (population PK), and biosimulation services. Nuventra is renowned for its track record of translating complex data into actionable insights across a range of therapeutic areas for more than 650 biopharmaceutical companies. Its team of scientific experts and senior consultants perform the industry’s foremost mathematical modeling and simulation techniques to inform clinical design and predict trial outcomes.

Companies are ranked on their revenue growth over a three-year period for this prestigious list. Of the tens of thousands of companies who apply, a very small fraction will make the list eight years in a row. A complete list of rankings and company profiles can be found on the Inc. 5000 website.